NP-G2-044 + anti-PD-1 Inhibitors
Solid Tumors
Key Facts
About Novita Pharmaceuticals
Novita Pharmaceuticals, founded in 2010, is dedicated to addressing the critical unmet need in oncology: cancer metastasis, which is responsible for over 90% of cancer-related deaths. The company's platform is built on the foundational discovery of the X-ray crystal structure of fascin, a key protein in cell motility, enabling the development of its lead candidate NP-G2-044. Currently in Phase 2A trials across 15 U.S. cancer centers, NP-G2-044 has shown promising safety and anti-tumor activity, including synergy with anti-PD-1 agents, and has received FDA Orphan Drug Designation for pancreatic cancer. Novita is strategically advancing its pipeline through monotherapy and combination regimens for a range of solid and hematological tumors.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| DM001 | Domabio | Phase 1 |
| DM002 | Domabio | Phase 1 |
| DM005 | Domabio | Phase 1 |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| CAR-T Solid Tumor Program | Carina Biotech | Phase 1/2a |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |